AMLX Q1 2025 Earnings — Amylyx Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMLXAmylyx Pharmaceuticals, Inc.

$1B

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

$0

Operating Income

-$38M

Net Income

-$36M

EPS (Diluted)

$-0.42

QoQ Revenue Growth

+100.0%

Cash Flow

Operating Cash Flow

-$40M

Free Cash Flow

-$40M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$220M

Total Liabilities

$18M

Stockholders' Equity

$201M

Cash & Equivalents

$60M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$89M	-100.0%
Gross Profit	$0	-$28M	+100.0%
Operating Income	-$38M	-$122M	+69.0%
Net Income	-$36M	-$119M	+69.8%